Soeiro CASP, et al. - Hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfected patients receiving HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) were evaluated for glomerular filtration rate (eGFR) change according to antiretroviral treatment (ARV). Based on ARV regimen, researchers categorized patients into three groups: non tenofovir (TDF), non-boosted TDF, and TDF plus boosted protease inhibitors. All study groups displayed a significant decrease in eGFR during treatment. Following SOF/LDV discontinuation, this decrease was small and reversible. No increased renal toxicity was observed in association with TDF.